Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing
Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant
Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study
Ensysce Biosciences Reports First Quarter 2026 Financial Results
Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam
Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
Ensysce Biosciences Expands Global Opioid Patent Portfolio
Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
Ensysce Biosciences Issues Annual Shareholder Letter
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach
Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
Ensysce Biosciences Reports Third Quarter 2025 Financial Results
Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025
Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium
Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025
Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates
Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback
Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse
Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025
Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection
Ensysce Biosciences Reports First Quarter 2025 Financial Results
Ensysce Biosciences Bolsters Management Team with Regulatory Expert
Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds
Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder
Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study
Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain
Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results
Ensysce Biosciences to Participate in the 37th Annual ROTH Conference